Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG GENES KEGG PATHWAY KEGG DRUG DrugBank Disease ID
1 CDK4 [11] p53 signaling pathway, PI3K-Akt signaling pathway, Tight junction, T cell receptor signaling pathway, Measles, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, Melanoma, Small cell lung cancer, Non-small cell lung cancer D10688 Abemaciclib [1] 34
2 CDK6 [10] p53 signaling pathway, PI3K-Akt signaling pathway, Measles, Pathways in cancer, Viral carcinogenesis, MicroRNAs in cancer, Pancreatic cancer, Melanoma, Small cell lung cancer, Non-small cell lung cancer D10688 Abemaciclib [1] 34
3 IFNA1 [9] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer D09662 Rontalizumab [1] 49
4 IFNA1 [9] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer D09668 Sifalimumab [1] 49
5 IFNA2 [9] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer D09662 Rontalizumab [1] 49
6 IFNA2 [9] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer D09668 Sifalimumab [1] 49
7 IFNA4 [9] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer D09662 Rontalizumab [1] 49
8 IFNA4 [9] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer D09668 Sifalimumab [1] 49
9 IFNA5 [9] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer D09662 Rontalizumab [1] 49
10 IFNA5 [9] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer D09668 Sifalimumab [1] 49
11 IFNA6 [9] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer D09662 Rontalizumab [1] 49
12 IFNA6 [9] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer D09668 Sifalimumab [1] 49
13 IFNA7 [9] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer D09662 Rontalizumab [1] 49
14 IFNA7 [9] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer D09668 Sifalimumab [1] 49
15 IFNA8 [9] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer D09662 Rontalizumab [1] 49
16 IFNA8 [9] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer D09668 Sifalimumab [1] 49
17 IFNA10 [9] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer D09662 Rontalizumab [1] 49
18 IFNA10 [9] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer D09668 Sifalimumab [1] 49
19 IFNA13 [9] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer D09662 Rontalizumab [1] 49
20 IFNA13 [9] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer D09668 Sifalimumab [1] 49
21 IFNA14 [9] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer D09662 Rontalizumab [1] 49
22 IFNA14 [9] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer D09668 Sifalimumab [1] 49
23 IFNA16 [9] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer D09662 Rontalizumab [1] 49
24 IFNA16 [9] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer D09668 Sifalimumab [1] 49
25 IFNA17 [9] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer D09662 Rontalizumab [1] 49
26 IFNA17 [9] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer D09668 Sifalimumab [1] 49
27 IFNA21 [9] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer D09662 Rontalizumab [1] 49
28 IFNA21 [9] PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Measles, Pathways in cancer D09668 Sifalimumab [1] 49
29 IFNAR1 [8] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Pathways in cancer D00745 Interferon alfa-2a [1] 56
30 IFNAR1 [8] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Pathways in cancer D00746 Interferon beta-1b [1] 13
31 IFNAR1 [8] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Pathways in cancer D02745 Interferon alfa-2b [2] 25, 34
32 IFNAR1 [8] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Pathways in cancer D03305 Interferon alfa [6] 13, 25, 26, 28, 56, 96
33 IFNAR1 [8] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Pathways in cancer D04554 Interferon beta-1a [4] 13, 26, 96, 97
34 IFNAR1 [8] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Pathways in cancer D10483 Peginterferon beta-1a [1] 13
35 IFNAR1 [8] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Pathways in cancer D11082 Anifrolumab [3] 46, 49, 53
36 IFNAR2 [8] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Pathways in cancer D00745 Interferon alfa-2a [1] 56
37 IFNAR2 [8] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Pathways in cancer D00746 Interferon beta-1b [1] 13
38 IFNAR2 [8] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Pathways in cancer D02745 Interferon alfa-2b [2] 25, 34
39 IFNAR2 [8] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Pathways in cancer D03305 Interferon alfa [6] 13, 25, 26, 28, 56, 96
40 IFNAR2 [8] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Pathways in cancer D04554 Interferon beta-1a [4] 13, 26, 96, 97
41 IFNAR2 [8] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Pathways in cancer D10483 Peginterferon beta-1a [1] 13
42 IFNAR2 [8] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Measles, Pathways in cancer D11082 Anifrolumab [3] 46, 49, 53
43 IL1A [10] Necroptosis, Osteoclast differentiation, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pertussis, Tuberculosis, Measles, Rheumatoid arthritis D01583 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
44 IL1A [10] Necroptosis, Osteoclast differentiation, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pertussis, Tuberculosis, Measles, Rheumatoid arthritis D06635 Rilonacept [4] 51, 106, 107, 266
45 IL1A [10] Necroptosis, Osteoclast differentiation, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pertussis, Tuberculosis, Measles, Rheumatoid arthritis D11253 Bermekimab [1] 51
46 IL1B [19] NF-kappa B signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Tuberculosis, Measles, Rheumatoid arthritis D01583 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
47 IL1B [19] NF-kappa B signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Tuberculosis, Measles, Rheumatoid arthritis D06635 Rilonacept [4] 51, 106, 107, 266
48 IL1B [19] NF-kappa B signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Tuberculosis, Measles, Rheumatoid arthritis D09315 Canakinumab [10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269
49 IL1B [19] NF-kappa B signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Tuberculosis, Measles, Rheumatoid arthritis D09911 Gevokizumab [4] 41, 50, 56, 269
50 IL2RA [6] Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Pathways in cancer D00748 Aldesleukin [6] 2, 35, 49, 65, 96, 97
51 IL2RA [6] Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Pathways in cancer D03058 Basiliximab [6] 2, 50, 66, 97, 222, 228
52 IL2RA [6] Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Pathways in cancer D03639 Daclizumab [8] 13, 56, 60, 65, 97, 107, 283, 284
53 IL2RB [7] Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Pathways in cancer, Transcriptional misregulation in cancer D00748 Aldesleukin [6] 2, 35, 49, 65, 96, 97
54 IL2RG [7] Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Pathways in cancer, Primary immunodeficiency D00748 Aldesleukin [6] 2, 35, 49, 65, 96, 97
55 IL6 [18] Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Yersinia infection, Tuberculosis, Measles, Pathways in cancer, Transcriptional misregulation in cancer, Rheumatoid arthritis D01583 Pirfenidone [11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
56 IL6 [18] Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Yersinia infection, Tuberculosis, Measles, Pathways in cancer, Transcriptional misregulation in cancer, Rheumatoid arthritis D08976 Pomalidomide [5] 28, 51, 85, 227, 331
57 IL6 [18] Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Yersinia infection, Tuberculosis, Measles, Pathways in cancer, Transcriptional misregulation in cancer, Rheumatoid arthritis D09669 Siltuximab [2] 28, 331
58 IL6 [18] Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Yersinia infection, Tuberculosis, Measles, Pathways in cancer, Transcriptional misregulation in cancer, Rheumatoid arthritis D10080 Sirukumab [2] 41, 46
59 IL6 [18] Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Th17 cell differentiation, TNF signaling pathway, Non-alcoholic fatty liver disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Yersinia infection, Tuberculosis, Measles, Pathways in cancer, Transcriptional misregulation in cancer, Rheumatoid arthritis D12487 Olokizumab [2] 46, 96
60 IL12A [9] Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Type I diabetes mellitus, Pertussis, Toxoplasmosis, Tuberculosis, Measles, Pathways in cancer D09214 Ustekinumab [16] 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271
61 IL12B [10] Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Type I diabetes mellitus, Pertussis, Toxoplasmosis, Tuberculosis, Measles, Pathways in cancer, Proteoglycans in cancer D09214 Ustekinumab [16] 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271
62 JAK1 [14] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Measles, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D09959 Ruxolitinib [3] 60, 65, 228
63 JAK1 [14] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Measles, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D09970 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300
64 JAK1 [14] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Measles, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10308 Baricitinib [13] 2, 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 269, 325
65 JAK1 [14] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Measles, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10653 Peficitinib [1] 46
66 JAK1 [14] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Measles, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10871 Filgotinib [6] 46, 53, 96, 97, 222, 271
67 JAK1 [14] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Measles, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10944 Itacitinib [4] 46, 51, 97, 228
68 JAK1 [14] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Measles, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D10994 Upadacitinib [8] 40, 41, 46, 49, 96, 97, 107, 271
69 JAK1 [14] PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Measles, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D11400 Abrocitinib [1] 84
70 JAK3 [10] PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Pathways in cancer, Viral carcinogenesis, Non-small cell lung cancer, Primary immunodeficiency D09970 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300
71 JAK3 [10] PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Pathways in cancer, Viral carcinogenesis, Non-small cell lung cancer, Primary immunodeficiency D10653 Peficitinib [1] 46
72 NFKB1 [34] Ras signaling pathway, NF-kappa B signaling pathway, Sphingolipid signaling pathway, PI3K-Akt signaling pathway, Osteoclast differentiation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Measles, Pathways in cancer, Transcriptional misregulation in cancer, Viral carcinogenesis, MicroRNAs in cancer, Pancreatic cancer, Prostate cancer, Small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D01146 Iguratimod [5] 46, 51, 53, 271, 300
73 TLR7 [3] Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Measles D02500 Imiquimod [2] 34, 51
74 PIK3CA [44] Metabolic pathways, Platinum drug resistance, Ras signaling pathway, Rap1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Measles, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Melanoma, Small cell lung cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D11011 Alpelisib [1] 138
75 PIK3CA [44] Metabolic pathways, Platinum drug resistance, Ras signaling pathway, Rap1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Measles, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Melanoma, Small cell lung cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D11158 Leniolisib [2] 53, 65
76 PIK3CB [44] Metabolic pathways, Platinum drug resistance, Ras signaling pathway, Rap1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Measles, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Melanoma, Small cell lung cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D11158 Leniolisib [2] 53, 65
77 PIK3CD [44] Metabolic pathways, Platinum drug resistance, Ras signaling pathway, Rap1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Measles, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Melanoma, Small cell lung cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D11158 Leniolisib [2] 53, 65
78 PIK3CD [44] Metabolic pathways, Platinum drug resistance, Ras signaling pathway, Rap1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Measles, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Melanoma, Small cell lung cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D11437 Parsaclisib [3] 35, 53, 61
79 TLR9 [5] Toll-like receptor signaling pathway, Salmonella infection, Tuberculosis, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer D12275 Cobitolimod [1] 97
80 BCL2 [20] Platinum drug resistance, NF-kappa B signaling pathway, Sphingolipid signaling pathway, p53 signaling pathway, Protein processing in endoplasmic reticulum, PI3K-Akt signaling pathway, Necroptosis, NOD-like receptor signaling pathway, Neurotrophin signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Shigellosis, Salmonella infection, Toxoplasmosis, Tuberculosis, Measles, Pathways in cancer, MicroRNAs in cancer, Prostate cancer, Small cell lung cancer D10679 Venetoclax [1] 28
81 RELA [34] Ras signaling pathway, NF-kappa B signaling pathway, Sphingolipid signaling pathway, Mitophagy - animal, PI3K-Akt signaling pathway, Osteoclast differentiation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Prolactin signaling pathway, Relaxin signaling pathway, Non-alcoholic fatty liver disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Measles, Pathways in cancer, Transcriptional misregulation in cancer, Viral carcinogenesis, Pancreatic cancer, Prostate cancer, Small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer D12181 Edasalonexent [1] 113
82 TYK2 [7] Necroptosis, Osteoclast differentiation, NOD-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Measles D09970 Tofacitinib [15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300
83 TYK2 [7] Necroptosis, Osteoclast differentiation, NOD-like receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Measles D11817 Deucravacitinib [3] 49, 96, 97
84 CASP9 [18] Platinum drug resistance, p53 signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, Thyroid hormone signaling pathway, Parkinson disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Toxoplasmosis, Tuberculosis, Measles, Pathways in cancer, Pancreatic cancer, Prostate cancer, Small cell lung cancer, Non-small cell lung cancer, Viral myocarditis D11195 Rimiducid [6] 19, 60, 65, 284, 285, 326
85 CD3D [6] Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency D06314 Visilizumab [2] 96, 97
86 CD3D [6] Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency D08959 Otelixizumab [1] 46
87 CD3E [6] Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency D06314 Visilizumab [2] 96, 97
88 CD3E [6] Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency D08959 Otelixizumab [1] 46
89 CD3E [6] Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency D11463 Mosunetuzumab [1] 49
90 CD3G [5] Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer D06314 Visilizumab [2] 96, 97
91 CD3G [5] Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer D08959 Otelixizumab [1] 46